ArticleEClinicalMedicine2024

Long-term efficacy and safety of continued complement C1s inhibition with sutimlimab in cold agglutinin disease: CADENZA study Part B.

Alexander Röth et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.